GRAIL (NASDAQ:GRAL) CFO Aaron Freidin Sells 7,900 Shares of Stock

by · The Markets Daily

GRAIL, Inc. (NASDAQ:GRAL – Get Free Report) CFO Aaron Freidin sold 7,900 shares of GRAIL stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $85.01, for a total value of $671,579.00. Following the sale, the chief financial officer directly owned 253,083 shares of the company’s stock, valued at $21,514,585.83. This trade represents a 3.03% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

GRAIL Price Performance

NASDAQ GRAL traded down $0.63 during trading hours on Monday, reaching $79.37. The stock had a trading volume of 555,941 shares, compared to its average volume of 781,912. GRAIL, Inc. has a 52-week low of $30.82 and a 52-week high of $118.84. The stock has a fifty day moving average of $71.28 and a 200 day moving average of $63.22.

GRAIL (NASDAQ:GRAL – Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($2.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.66) by $0.10. GRAIL had a negative net margin of 236.95% and a negative return on equity of 15.88%. The company had revenue of $44.69 million during the quarter, compared to analyst estimates of $42.39 million. On average, sell-side analysts expect that GRAIL, Inc. will post -10.41 earnings per share for the current year.

Hedge Funds Weigh In On GRAIL

Large investors have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd acquired a new position in shares of GRAIL in the fourth quarter worth about $28,000. Elyxium Wealth LLC purchased a new position in shares of GRAIL in the 4th quarter valued at about $31,000. Comerica Bank increased its stake in shares of GRAIL by 59.2% in the 3rd quarter. Comerica Bank now owns 465 shares of the company’s stock valued at $27,000 after purchasing an additional 173 shares in the last quarter. Fifth Third Bancorp raised its holdings in GRAIL by 15,733.3% in the 1st quarter. Fifth Third Bancorp now owns 475 shares of the company’s stock worth $25,000 after purchasing an additional 472 shares during the period. Finally, Allworth Financial LP acquired a new stake in GRAIL in the second quarter valued at approximately $35,000.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Piper Sandler raised their target price on shares of GRAIL from $54.00 to $56.00 and gave the stock a “neutral” rating in a report on Wednesday, May 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of GRAIL in a research report on Friday, July 17th. TD Cowen reissued a “buy” rating on shares of GRAIL in a report on Wednesday, July 15th. Mizuho upped their target price on GRAIL from $58.00 to $65.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 15th. Finally, Wolfe Research began coverage on GRAIL in a report on Tuesday, June 2nd. They set a “peer perform” rating on the stock. Four research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $67.78.

Check Out Our Latest Analysis on GRAL

GRAIL Company Profile

(Get Free Report)

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.

Featured Articles